"Mucormycosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Infection in humans and animals caused by any fungus in the order Mucorales (e.g., Absidia, Mucor, Rhizopus etc.) There are many clinical types associated with infection of the central nervous system, lung, gastrointestinal tract, skin, orbit and paranasal sinuses. In humans, it usually occurs as an opportunistic infection in patients with a chronic debilitating disease, particularly uncontrolled diabetes, or who are receiving immunosuppressive agents. (From Dorland, 28th ed)
| Descriptor ID |
D009091
|
| MeSH Number(s) |
C01.703.980.600
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mucormycosis".
Below are MeSH descriptors whose meaning is more specific than "Mucormycosis".
This graph shows the total number of publications written about "Mucormycosis" by people in this website by year, and whether "Mucormycosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 4 | 0 | 4 |
| 2010 | 2 | 0 | 2 |
| 2011 | 9 | 0 | 9 |
| 2012 | 10 | 2 | 12 |
| 2013 | 4 | 1 | 5 |
| 2014 | 7 | 1 | 8 |
| 2015 | 2 | 2 | 4 |
| 2016 | 6 | 0 | 6 |
| 2017 | 2 | 0 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 5 | 0 | 5 |
| 2022 | 2 | 0 | 2 |
| 2023 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mucormycosis" by people in Profiles.
-
Mucormycosis in 2023: an update on pathogenesis and management. Front Cell Infect Microbiol. 2023; 13:1254919.
-
Mucormycosis: update on clinical presentation, diagnosis, and treatment. Curr Opin Infect Dis. 2023 12 01; 36(6):427-435.
-
Multimodal analysis of the COVID-19-associated mucormycosis outbreak in Delhi, India indicates the convergence of clinical and environmental risk factors. Mycoses. 2023 Jun; 66(6):515-526.
-
Are Unique Regional Factors the Missing Link in India's COVID-19-Associated Mucormycosis Crisis? mBio. 2022 04 26; 13(2):e0047322.
-
Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis. Front Immunol. 2022; 13:838344.
-
Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study. Mycoses. 2022 Feb; 65(2):186-198.
-
Can low-dose radiation therapy reduce the risk of mucormycosis in COVID-19 patients? J Cancer Res Ther. 2021 Oct-Dec; 17(6):1294-1296.
-
Healthcare-associated Pediatric Cutaneous Mucormycosis at Texas Children's Hospital, 2012-2019. Pediatr Infect Dis J. 2021 08 01; 40(8):746-748.
-
Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol. 2021 07; 69(7):1670-1692.
-
Mucormycosis-A serious threat in the COVID-19 pandemic? J Infect. 2021 08; 83(2):237-279.